SABS Stock Overview A clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
SAB Biotherapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for SAB Biotherapeutics Historical stock prices Current Share Price US$4.65 52 Week High US$7.52 52 Week Low US$2.16 Beta 0.60 1 Month Change 48.56% 3 Month Change 55.00% 1 Year Change -33.67% 3 Year Change -94.69% 5 Year Change n/a Change since IPO -95.42%
Recent News & Updates
Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) Nov 08
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely Sep 22
Price target decreased by 35% to US$13.00 Aug 15
Consensus revenue estimates increase by 30% Aug 15
Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes Aug 06
SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024 Jul 31 See more updates
Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) Nov 08
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely Sep 22
Price target decreased by 35% to US$13.00 Aug 15
Consensus revenue estimates increase by 30% Aug 15
Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes Aug 06
SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024 Jul 31 SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics May 23 SAB Biotherapeutics, Inc. announced delayed 10-Q filing May 17
SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors May 08
SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update Apr 16
Price target increased by 25% to US$25.00 Apr 03
New major risk - Revenue and earnings growth Apr 02
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 01
New minor risk - Share price stability Mar 20
SAB Biotherapeutics, Inc. Announces CEO Changes Feb 02
SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Jan 28 SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million. Jan 27
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Jan 24
New major risk - Shareholder dilution Dec 21
SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142 Nov 29
SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors Nov 21
Consensus revenue estimates increase by 61% Nov 20
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 16
Price target decreased by 22% to US$2.50 Nov 14 SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer Oct 25
SAB Biotherapeutics Appoints Andrew Moin to Board of Directors Oct 06
Consensus revenue estimates decrease by 51%, EPS upgraded May 26
Consensus revenue estimates decrease by 81%, EPS upgraded May 22
SAB Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2023 May 20
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 17
SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies May 13
SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform May 10
SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference May 05
Consensus revenue estimates decrease by 56%, EPS upgraded Apr 21
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified Apr 17
Full year 2022 earnings released: US$0.43 loss per share (vs US$0.63 loss in FY 2021) Apr 16
Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week Jan 20
SAB Biotherapeutics, Inc. Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes Jan 12 SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases SAB Biotherapeutics, Inc. announced that it has received $7.884 million in funding Dec 09
SAB Biotherapeutics Inc. Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes Nov 22
Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues Nov 19
Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts Nov 18
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 17
High number of new directors Nov 16
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference Nov 04
SAB Biotherapeutics Receives a Written Notification from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement Oct 10
Sab Biotherapeutics Unveils New Data At Isirv Options XI Conference Validating SAB-176 Proof of Concept Sep 29
SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial Sep 28
SAB Biotherapeutics to Present New Data At Isirv Options Xi Conference on Sab-176 Phase 2A Influenza Trial and Sab-185’S Effectiveness Against Multiple Covid-19 Variants Sep 24
Consensus revenue estimates fall by 41% Aug 17
What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates Aug 12
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 11
SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03 Aug 10
SAB Biotherapeutics, Inc. Appoints Rear Admiral Scott Giberson to Board of Directors Jul 12
SAB Biotherapeutics, Inc. Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer Jun 07
SAB Biotherapeutics, Inc., Annual General Meeting, Jul 06, 2022 May 27
Consensus forecasts updated May 19
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13
Price target decreased to US$10.35 Apr 27
High number of new directors Apr 27
High number of new directors Apr 06
Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term Apr 06
SAB Biotherapeutics, Inc. Appoints Mark J. Ratain to Its Board of Scientific Advisors Apr 06
Consensus revenue estimates fall by 25% Apr 05
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 30
Price target decreased to US$12.63 Mar 04
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations Mar 04
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19 Feb 26
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19 Jan 25
High number of new directors Jan 01
Consensus EPS estimates increase to -US$0.23 Dec 03
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus Dec 02
SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies Dec 02
Third quarter 2021 earnings: EPS and revenues miss analyst expectations Nov 25
Investor sentiment improved over the past week Nov 12
No independent directors Oct 27 Shareholder Returns SABS US Biotechs US Market 7D 14.0% -3.6% -2.4% 1Y -33.7% -2.6% 23.4%
See full shareholder returns
Return vs Industry: SABS underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: SABS underperformed the US Market which returned 23.3% over the past year.
Price Volatility Is SABS's price volatile compared to industry and market? SABS volatility SABS Average Weekly Movement 22.7% Biotechs Industry Average Movement 10.8% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SABS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SABS's weekly volatility has increased from 16% to 23% over the past year.
About the Company SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma.
Show more SAB Biotherapeutics, Inc. Fundamentals Summary How do SAB Biotherapeutics's earnings and revenue compare to its market cap? SABS fundamental statistics Market cap US$42.92m Earnings (TTM ) -US$45.57m Revenue (TTM ) US$1.51m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SABS income statement (TTM ) Revenue US$1.51m Cost of Revenue US$26.90m Gross Profit -US$25.38m Other Expenses US$20.18m Earnings -US$45.57m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.94 Gross Margin -1,678.08% Net Profit Margin -3,012.27% Debt/Equity Ratio 0%
How did SABS perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:25 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SAB Biotherapeutics, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kumaraguru Raja Brookline Capital Markets Keay Nakae Chardan Capital Markets, LLC Gum-Ming Lowe Craig-Hallum Capital Group LLC
Show 3 more analysts 
